251 related articles for article (PubMed ID: 32453653)
1. Effects of CYP3A5, ABCB1 and POR*28 polymorphisms on pharmacokinetics of tacrolimus in the early period after renal transplantation.
Ling J; Dong LL; Yang XP; Qian Q; Jiang Y; Zou SL; Hu N
Xenobiotica; 2020 Dec; 50(12):1501-1509. PubMed ID: 32453653
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic analysis and dosing guidelines for tacrolimus co-administration with Wuzhi capsule in Chinese renal transplant recipients.
Jing Y; Kong Y; Hou X; Liu H; Fu Q; Jiao Z; Peng H; Wei X
J Clin Pharm Ther; 2021 Aug; 46(4):1117-1128. PubMed ID: 33768546
[TBL] [Abstract][Full Text] [Related]
3. Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T/A polymorphism on pharmacokinetics of Tacrolimus in Chinese adult liver transplant patients.
Zhu L; Yang J; Zhang Y; Jing Y; Zhang Y; Li G
Xenobiotica; 2015; 45(9):840-6. PubMed ID: 25869250
[TBL] [Abstract][Full Text] [Related]
4. Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients.
Han N; Yun HY; Hong JY; Kim IW; Ji E; Hong SH; Kim YS; Ha J; Shin WG; Oh JM
Eur J Clin Pharmacol; 2013 Jan; 69(1):53-63. PubMed ID: 22660440
[TBL] [Abstract][Full Text] [Related]
5. Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.
Shi XJ; Geng F; Jiao Z; Cui XY; Qiu XY; Zhong MK
J Clin Pharm Ther; 2011 Oct; 36(5):614-24. PubMed ID: 21916909
[TBL] [Abstract][Full Text] [Related]
6. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.
Ogasawara K; Chitnis SD; Gohh RY; Christians U; Akhlaghi F
Clin Pharmacokinet; 2013 Sep; 52(9):751-62. PubMed ID: 23633119
[TBL] [Abstract][Full Text] [Related]
7. Tacrolimus population pharmacokinetics according to CYP3A5 genotype and clinical factors in Chinese adult kidney transplant recipients.
Zhang HJ; Li DY; Zhu HJ; Fang Y; Liu TS
J Clin Pharm Ther; 2017 Aug; 42(4):425-432. PubMed ID: 28401703
[TBL] [Abstract][Full Text] [Related]
8. The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.
Zhang JJ; Liu SB; Xue L; Ding XL; Zhang H; Miao LY
Int J Clin Pharmacol Ther; 2015 Sep; 53(9):728-36. PubMed ID: 26227094
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetic analysis of tacrolimus in Mexican paediatric renal transplant patients: role of CYP3A5 genotype and formulation.
Jacobo-Cabral CO; García-Roca P; Romero-Tejeda EM; Reyes H; Medeiros M; Castañeda-Hernández G; Trocóniz IF
Br J Clin Pharmacol; 2015 Oct; 80(4):630-41. PubMed ID: 25846845
[TBL] [Abstract][Full Text] [Related]
10. Tacrolimus population pharmacokinetic models according to CYP3A5/CYP3A4/POR genotypes in Chinese Han renal transplant patients.
Zhu W; Xue L; Peng H; Duan Z; Zheng X; Cao D; Wen J; Wei X
Pharmacogenomics; 2018 Aug; 19(13):1013-1025. PubMed ID: 30040022
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients.
Prytuła AA; Cransberg K; Bouts AH; van Schaik RH; de Jong H; de Wildt SN; Mathôt RA
Clin Pharmacokinet; 2016 Sep; 55(9):1129-43. PubMed ID: 27138785
[TBL] [Abstract][Full Text] [Related]
12. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.
Zuo XC; Ng CM; Barrett JS; Luo AJ; Zhang BK; Deng CH; Xi LY; Cheng K; Ming YZ; Yang GP; Pei Q; Zhu LJ; Yuan H; Liao HQ; Ding JJ; Wu D; Zhou YN; Jing NN; Huang ZJ
Pharmacogenet Genomics; 2013 May; 23(5):251-61. PubMed ID: 23459029
[TBL] [Abstract][Full Text] [Related]
13. Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms.
Op den Buijsch RA; Christiaans MH; Stolk LM; de Vries JE; Cheung CY; Undre NA; van Hooff JP; van Dieijen-Visser MP; Bekers O
Fundam Clin Pharmacol; 2007 Aug; 21(4):427-35. PubMed ID: 17635182
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic-pharmacogenetic model of tacrolimus in the early period after kidney transplantation.
Han N; Ha S; Yun HY; Kim MG; Min SI; Ha J; Lee JI; Oh JM; Kim IW
Basic Clin Pharmacol Toxicol; 2014 May; 114(5):400-6. PubMed ID: 24238261
[TBL] [Abstract][Full Text] [Related]
15. CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III).
Yoon SH; Cho JH; Kwon O; Choi JY; Park SH; Kim YL; Yoon YR; Won DI; Kim CD
Transplantation; 2013 Mar; 95(6):828-34. PubMed ID: 23364483
[TBL] [Abstract][Full Text] [Related]
16. Impact of POR and CYP3A5 Polymorphisms on Trough Concentration to Dose Ratio of Tacrolimus in the Early Post-operative Period Following Kidney Transplantation.
Phupradit A; Vadcharavivad S; Ingsathit A; Kantachuvesiri S; Areepium N; Sra-Ium S; Auamnoy T; Sukasem C; Sumethkul V; Kitiyakara C
Ther Drug Monit; 2018 Oct; 40(5):549-557. PubMed ID: 29878980
[TBL] [Abstract][Full Text] [Related]
17. Effects of Postoperative Day and NR1I2 on Tacrolimus Clearance in Chinese Liver Transplant Recipients-A Population Model Approach.
Lu Y; Xu L; Cui J; Shen S; Li X
Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1385-1394. PubMed ID: 34133842
[TBL] [Abstract][Full Text] [Related]
18. Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients.
Marquet P; Albano L; Woillard JB; Rostaing L; Kamar N; Sakarovitch C; Gatault P; Buchler M; Charpentier B; Thervet E; Cassuto E
Pharmacol Res; 2018 Mar; 129():84-94. PubMed ID: 29229354
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in Chinese liver transplant patients.
Chen B; Shi HQ; Liu XX; Zhang WX; Lu JQ; Xu BM; Chen H
J Clin Pharm Ther; 2017 Dec; 42(6):679-688. PubMed ID: 28833329
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose.
Bergmann TK; Hennig S; Barraclough KA; Isbel NM; Staatz CE
Ther Drug Monit; 2014 Feb; 36(1):62-70. PubMed ID: 24089074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]